Comparison of High-sensitivity C-reactive Protein Level between Chronic Kidney Disease Stages
Downloads
ABSTRACT
Aim : This research is to evaluate the hs-CRP level comparison between CKD stages in Dr. Soetomo General Hospital Surabaya.
Methods: An analytic observational cross-sectional study, evaluating the differences of hs-CRP level between CKD stages in 72 patients (mean age 55.49±7.62 years, the ratio between male:female was 1:1.48, mean BMI 24.18±3.64 kg/m2, 36.11% diabetics, 43.05% on ACEI/ARB, 29.16% on statin), recruited from Nephrology Outpatient Clinic, Dr Soetomo General Hospital, Surabaya, from January to May 2014. The stages were stratified according to the MDRD formula.
Results: The mean hs-CRP of CKD stage 3 was 2.29±2.86, stage 4 was 2.48 ± 2.19, and non-dialysis stage 5 was 2.09 ± 2.54. The analysis using Kruskal-Wallis test showed no significant differences among patients with CKD stage 3, stage 4, and non-dialysis stage 5 (median 1.25 vs 1.80 vs 1.05 mg/L; p=0.430). No significant differences of the serum hs-CRP level were detected between diabetics and non diabetics in stage 3, 4, and non-dialysis stage 5 (p=0.673 vs 0.666 vs 0.138); between patients with and without ACEI/ARB treatment (p=0.610 vs 0.649 vs 0.671); and between patients with and without statin treatment (p=0.852 vs 0.341 vs 0.309).
Conclusion: The elevation of serum hs-CRP level can not indicate the decline of kidney function, but it still needs further investigations.
REFERENCES
Fasset et al., 2011. Biomarkers in chronic kidney disease: a review. Kidney Int 80: 806-21 doi: 10.1038/ki.2011.198
RSDS, 2013. Data penderita penyakit ginjal kronik dan kunjungan hemodialisis di RSUD Dr. Soetomo Surabaya tahun 2008-2012. Sistim Informasi Manajemen RSUD Dr. Soetomo Surabaya, Surabaya
López-Novoa JM, Rodriguez-Perla AB, Ortiz A, Martinez-Salgado C and Lopez-Hernandez FJ, 2011. ‘Etiopathology of chronic tubular, glomerular and renovascular nephropaties: clinical implications'. Journal of Translational Medicine 9:13 doi: 10.1186/1479-5876-9-13
Lavin-Gomez BA, Palomar-Fontanet R, Gago-Fraile M, Quintanar-Lartundo JA, Gomez-Palomo E, Gonzalez-Lamuno D, et al., 2011. ‘Inflammation markers, chronic kidney disease, and renal replacement therapy'. Advances in Peritoneal Dialysis 27:33-37 PMID: 22073825
Kalantar-Zadeh K, 2007. ‘Inflammatory marker mania in chronic kidney disease: Pentraxins at the crossroad of universal soldiers of inflammation'. Clinical Journal of The American Society of Nephrology 2:872-875 doi: 10.2215/CJN.02750707
Kurts C, Panzer U, Anders HJ and Rees AJ, 2013.'The immune system and kidney disease: basic concepts and clinical implications'. Nature Review Immunology 13:738-753 doi: 10.1038/nri3523
Cohen G and Hörl WH, 2012. ‘Immune dysfunction in uremia-An update'. Toxins 4: 962-990 doi: 10.3390/toxins4110962
Lacson E and Levin NW, 2004. ‘C-reactive protein and End-Stage Renal Disease'. Seminars in Dialysis 17: 438-448 PMID: 15660574
Autoimmunity Research Foundation, 2012. Test: C-Reactive Protein (CRP), viewed May 14th 2013, <http://mpkb.org/home/tests/crp>
Abraham G, Sundaram V, Sundaram V, Mathew M, Leslie N and Sthiah V, 2009. ‘C-reactive protein, a valuable predictive marker in chronic kidney disease'. Saudi Journal of Kidney Diseases and Transplantation 20: 811-815 PMID: 19736479
Clyne B and Olshaker JS, 1999. ‘The C-reactive protein'. Journal of Emerging Medicine 17 (6): 1019–1025 PMID: 10595891
Fox ER, Benjamin EJ, Sarpong DF, Nagarajarao H, Taylor JK and Steffes MW, et al, 2010. ‘The relation of C-reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study'. BioMed Central of Nephrology 11:1 doi: 10.1186/1471-2369-11-1
Romí£o JE Jr, Haiashi AR, Elias RM, Luders C, Ferraboli R, Castro MC and Abensur H, 2006. ‘Positive acute-phase inflammatory markers in different stages of chronic kidney disease'. American Journal of Nephrology 26:59-66 PMID: 16508248
Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B and Stenvinkel P, 2003. ‘Associations Between Circulating Inflammatory Markers and Residual Renal Function in CRF Patients'. American Journal of Kidney Diseases 41:1212-18 PMID: 12776273
Pepys MB and Hirschfield GM, 2003. ‘C-reactive protein: a critical update'. Journal of Clinical Investigation 111:1805-1812 doi: 10.1172/JCI200318921
Grzegorczyk K, Krajewska M, Weyde W, Jakuszko K, Gniewek A and Klinger M, 2011. ‘Gender and kidney disease: the clinical importance and mechanisms of modifying effects'. Postepy Higieny i Medycyny Doswiadczalnej 65:849-57 PMID: 22204762
Silbiger S and Neugarten F, 2008.'Gender and human chronic renal disease'. Gender Medicine 5:S3-S10 doi: 10.1016/j.genm.2008.03.002
Wang CS and Sun CF, 2009. ‘C-Reactive Protein and Malignancy: Clinico-pathological Association and Therapeutic Implication'. Chang Gung Medical Journal 32: 471-82
Savoia C and Schiffrin EL, 2007. ‘Reduction of C-reactive protein and the use of anti-hypertensives'. Vascular Health and Risk Management 3:975-83 PMCID: PMC2350124
Ridker PM, Rifai N, Pfeffer MA, Sacks F and Braunwald E, 1999.'Long-term effects of pravastatin on plasma concentration of C-reactive protein'. Circulation 100:230-235 PMID: 10411845
Icardi A, Paoletti E, Nicola LD, Mazzaferro S, Russo R and Cozzolino M, 2013.'Renal anemia and EPO hyporesponsiveness associated with vitaminD deficiency'. Nephrology Dialysis Transplantation 28(7):1672-79 doi: 10.1093/ndt/gft021
KDIGO, 2013. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements 3: 19-62
Leeder SR, Mitchell P, Liew G, Rochtchina E, Smith W, and Wang JJ, 2006.'Low hemoglobin, chronic kidney disease, and risk for coronary heart disease-related death: the blue mountains eye study'. Journal of The American Society of Nephrology 17:279-284 PMID: 16319191
Ketteler M, 2011.'Phosphate metabolism in CKD stages 3-5: dietary and pharmacological control'. International Journal of Nephrology 2011:970245 doi: 10.4061/2011/970245
Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, et al., 2008.'Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysys'. Clinical Journal of The American Society of Nephrology 3(4):1125-30 doi: 10.2215/CJN.05161107
Bargman & Skorecki, 2008. Chronic kidney disease. In (Faucy AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds). Harrison's principles of internal medicine, 17th edition, USA: McGraw-Hill Companies, Inc, 1761-1775
Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Gallimore JR, et al., 2004. ‘Obesity is an Important Determinant of Baseline Serum C-Reactive Protein Concentration in Monozygotic Twins, Independent of Genetics Influences'. Circulation 109: 3022-28 PMID: 15184288
Visser M, Bouter LM, McQuillan GM, Wener MH and Harris TB, 1999. ‘Elevated C-Reactive Protein Levels in Overweight and Obese Adults'. Journal of American Medical Association 282: 2131-35 PMID: 10591334
Schwedler SB, Filep JG, Galle J, Wanner C and Potempa LA, 2006. ‘C-reactive protein: a family of proteins to regulate cardiovascular function'. American Journal of Kidney Diseases 47: 212-222 PMID: 16431250
Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al., 2008.'Aspects of immune dysfunction in end-stage renal disease'. Clinical Journal of The American Society of Nephrology 3:1526-33 doi: 10.2215/CJN.00950208
Dobrian AC, 2012. ‘ADMA and NOS regulation in chronic renal disease: beyond the old rivalry for L-arginine'. Kidney International 81:722-724 doi: 10.1038/ki.2011.496
Mugabo Y, Li L and Renier G, 2010. ‘The connection between C-reactive protein and diabetic vasculopaty. Focus on preclinical findings'. Current Diabetes Reviews 6(1):27-34 PMID: 20034371
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
